Literature DB >> 10572005

Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.

R Bai1, N A Durso, D L Sackett, E Hamel.   

Abstract

The sponge-derived antimitotic tripeptide hemiasterlin was previously shown to inhibit tubulin polymerization. We have now demonstrated that hemiasterlin resembles most other antimitotic peptides in noncompetitively inhibiting the binding of vinblastine to tubulin (apparent K(i) value, 7.0 microM), competitively inhibiting the binding of dolastatin 10 to tubulin (apparent K(i) value, 2.0 microM), stabilizing the colchicine binding activity of tubulin, inhibiting nucleotide exchange on beta-tubulin, and inducing the formation of tubulin oligomers that are stable to gel filtration in the absence of free drug, even at low drug concentrations. The tubulin oligomerization reaction induced by hemiasterlin was compared to the reactions induced by dolastatin 10 and cryptophycin 1. Like dolastatin 10, hemiasterlin induced formation of a tubulin aggregate that had the morphological appearance primarily of ring-like structures with a diameter of about 40 nm, while the morphology of the cryptophycin 1 aggregate consisted primarily of smaller rings (diameter about 30 nm). However, the hemiasterlin aggregate differed from the dolastatin 10 aggregate in that its formation was not associated with turbidity development, and the morphology of the hemiasterlin aggregate (as opposed to the dolastatin 10 aggregate) did not change greatly when microtubule-associated proteins were present (tight coils and pinwheels are observed with dolastatin 10 but not with hemiasterlin or cryptophycin 1). Opacification of tubulin-dolastatin 10 mixtures was inhibited by hemiasterlin at 22 degrees C and stimulated at 0 degrees C, while cryptophycin 1 was inhibitory at both reaction temperatures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572005     DOI: 10.1021/bi991323e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

2.  Visualisation of a kinesin-13 motor on microtubule end mimics.

Authors:  Carolyn A Moores; Ronald A Milligan
Journal:  J Mol Biol       Date:  2008-02-04       Impact factor: 5.469

Review 3.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

4.  Structural insight into the inhibition of tubulin by vinca domain peptide ligands.

Authors:  Anthony Cormier; Matthieu Marchand; Raimond B G Ravelli; Marcel Knossow; Benoît Gigant
Journal:  EMBO Rep       Date:  2008-09-12       Impact factor: 8.807

5.  Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation.

Authors:  Giordano Lesma; Alessandro Sacchetti; Rouli Bai; Giuseppe Basso; Roberta Bortolozzi; Ernest Hamel; Alessandra Silvani; Nadia Vaiana; Giampietro Viola
Journal:  Mol Divers       Date:  2014-02-06       Impact factor: 2.943

6.  Complementary isonitrile-based multicomponent reactions for the synthesis of diversified cytotoxic hemiasterlin analogues.

Authors:  Giordano Lesma; Ivan Bassanini; Roberta Bortolozzi; Chiara Colletto; Ruoli Bai; Ernest Hamel; Fiorella Meneghetti; Giulia Rainoldi; Mattia Stucchi; Alessandro Sacchetti; Alessandra Silvani; Giampietro Viola
Journal:  Org Biomol Chem       Date:  2015-10-15       Impact factor: 3.876

7.  Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Authors:  Lih-Ching Hsu; David E Durrant; Ching-Chun Huang; Nai-Wen Chi; Riccardo Baruchello; Riccardo Rondanin; Cinzia Rullo; Paolo Marchetti; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2011-06-08       Impact factor: 3.850

8.  Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.

Authors:  Terry W Moody; Tapas Pradhan; Samuel A Mantey; Robert T Jensen; Marcin Dyba; Deborah Moody; Nadya I Tarasova; Christopher J Michejda
Journal:  Life Sci       Date:  2008-02-14       Impact factor: 5.037

9.  The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.

Authors:  J Torin Huzil; Ke Chen; Lukasz Kurgan; Jack A Tuszynski
Journal:  Cancer Inform       Date:  2007-04-27

10.  A new model for binding of kinesin 13 to curved microtubule protofilaments.

Authors:  Anke M Mulder; Alex Glavis-Bloom; Carolyn A Moores; Michael Wagenbach; Bridget Carragher; Linda Wordeman; Ronald A Milligan
Journal:  J Cell Biol       Date:  2009-03-30       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.